Dr. Thomas Chiesl, PhD
New Technology and Microfluidic Development Lead
Ibis Biosciences, a division of Abbott Labs
Thursday, February 18, 2016 6:00 pm (Food starting at 5:30 pm)
Blum Hall B100
-----------------------------------------------------------------------------------------------------------------
Development of the Mobile Analysis Platform (MAPs)
Dr. Chiesl will discuss:
1. i-STAT, a mature Abbott technology, the i-STAT, which has production of over 1 million cartridges per month and is arguably the most successful point of care device in existence.
2. MAPs (mobile analysis platform), a platform in the R&D phase which also seeks to cross the “diagnostic development valley of death”. The MAPs device is a truly field-portable hand-held battery operated device capable of performing highly multiplexed RT-PCR using a microfluidic cartridge with minimal training and returns answers in ~1 hour with assays for a wide variety of pathogens such as Ebola, Flu, Anthrax, STDs, and Zika virus
Background:
The field of microfluidics has transformed the way researchers investigate chemical and biological phenomenon by miniaturizing the scale of reagent manipulation and sample analysis. The potential for microfluidics in conjunction with point of care instrumentation is tremendous yet success and wide spread adoption in the commercial arena is lagging behind. One of the standby jokes told at conferences still remains: “Is it a lab-on-a-chip or a chip-in-a-lab?” Another criticism regarding the field is that microfluidic devices often generate elegant solutions to problems that nobody is desperate to solve. Successful commercial deployment requires both a functional product and a receptive market eager to adopt it for an identifiable cost- or performance-related reason.
-----------------------------------------------------------------------------------------------------------------
About Dr. Chiesl:
Dr. Thomas N. Chiesl has spent his research career in development of bioanalytical techniques, chemistry, microfabrication / microfluidics, and instrumentation development. His Ph.D. and Post-Doctoral research in the labs of Dr. Annelise Barron and Dr. Rich Mathies (UC Berkeley) has focused on development of materials (polymeric and nanoparticles) for use in microfluidic devices and the integration and optimization of electrophoretic analysis techniques applied towards molecular analysis of organic compounds. He has experience in the design, fabrication, and implementation of glass and injection-molded plastic microfluidic devices and has experience developing microfluidic systems for NASA / JPL and was a part of the extended science team on the Urey instrument package on the ExoMars mission. At Ibis, Tom works on new technology
development and leads developmental efforts in microfluidics, hand-held instrumentation, detection chemistry, ultra-fast 15 min PCR, and nanopore technology. Dr. Chiesl’s continuing goals are to establish academic collaborations the bridge the gap between academia and industry, develop new technology, and adapt and transition new technology into products that will positively impact people’s health and happiness.
New Technology and Microfluidic Development Lead
Ibis Biosciences, a division of Abbott Labs
Thursday, February 18, 2016 6:00 pm (Food starting at 5:30 pm)
Blum Hall B100
-----------------------------------------------------------------------------------------------------------------
Development of the Mobile Analysis Platform (MAPs)
Dr. Chiesl will discuss:
1. i-STAT, a mature Abbott technology, the i-STAT, which has production of over 1 million cartridges per month and is arguably the most successful point of care device in existence.
2. MAPs (mobile analysis platform), a platform in the R&D phase which also seeks to cross the “diagnostic development valley of death”. The MAPs device is a truly field-portable hand-held battery operated device capable of performing highly multiplexed RT-PCR using a microfluidic cartridge with minimal training and returns answers in ~1 hour with assays for a wide variety of pathogens such as Ebola, Flu, Anthrax, STDs, and Zika virus
Background:
The field of microfluidics has transformed the way researchers investigate chemical and biological phenomenon by miniaturizing the scale of reagent manipulation and sample analysis. The potential for microfluidics in conjunction with point of care instrumentation is tremendous yet success and wide spread adoption in the commercial arena is lagging behind. One of the standby jokes told at conferences still remains: “Is it a lab-on-a-chip or a chip-in-a-lab?” Another criticism regarding the field is that microfluidic devices often generate elegant solutions to problems that nobody is desperate to solve. Successful commercial deployment requires both a functional product and a receptive market eager to adopt it for an identifiable cost- or performance-related reason.
-----------------------------------------------------------------------------------------------------------------
About Dr. Chiesl:
Dr. Thomas N. Chiesl has spent his research career in development of bioanalytical techniques, chemistry, microfabrication / microfluidics, and instrumentation development. His Ph.D. and Post-Doctoral research in the labs of Dr. Annelise Barron and Dr. Rich Mathies (UC Berkeley) has focused on development of materials (polymeric and nanoparticles) for use in microfluidic devices and the integration and optimization of electrophoretic analysis techniques applied towards molecular analysis of organic compounds. He has experience in the design, fabrication, and implementation of glass and injection-molded plastic microfluidic devices and has experience developing microfluidic systems for NASA / JPL and was a part of the extended science team on the Urey instrument package on the ExoMars mission. At Ibis, Tom works on new technology
development and leads developmental efforts in microfluidics, hand-held instrumentation, detection chemistry, ultra-fast 15 min PCR, and nanopore technology. Dr. Chiesl’s continuing goals are to establish academic collaborations the bridge the gap between academia and industry, develop new technology, and adapt and transition new technology into products that will positively impact people’s health and happiness.
RSS Feed